A critical review of variables affecting the accuracy and false-negative rate of sentinel node biopsy procedures in early breast cancer

Nuclear Medicine Communications

Volumn 26, Issue 5, 2005, Pages 395-405

  Vijayakumar, Vani ^a   Boerner, Philip S ^a   Jani, Ashesh B ^a   Vijayakumar, Srinivasan ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Breast cancer; False negative rate; Sentinel lymph node (SLN); SLN biopsy; SLN identification rate

Indexed keywords

ADJUVANT THERAPY; AGE; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; HUMAN; INJECTION SITE; LABORATORY DIAGNOSIS; MULTIPLE CANCER; PATHOPHYSIOLOGY; REVIEW; SCINTISCANNING; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SURGICAL TRAINING; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CLINICAL TRIALS; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENTINEL LYMPH NODE BIOPSY;

EID: 18144368926     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200505000-00002     Document Type: Review

References (149)

1. American Cancer Society. Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2004: p. 4. http://www.cancer.org/docroot/STT/stt_0.asp
2. Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 1968; 168:337-356.
3. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983; 52:1551-1557.
4. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332:901-906.
5. McMasters KM, Giuliano AE, Ross MI, Reintgen DS, Hunt KK, Byrd DR, et al. Sentinel-lymph-node biopsy for breast cancer - not yet the standard of care. N Engl J Med 1998; 339:990-995.
6. 99mTc facilitates sentinel lymph node identification. Ann Surg Oncol 2002; 9:77-81.
7. Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June 1889 to January 1894. Johns Hopkins Hosp Bull 1894-1895; 4:297-323.
8. Harris JR, Osteen RT. Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res Treat 1985; 5:17-21.
9. Morrow M. Role of axillary dissection in breast cancer management. Ann Surg Oncol 1996; 3:233-234.
10. Lin PP, Allison DC, Wainstock J, Miller KD, Dooley WC, Friedman N, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993; 11:1536-1544.
11. Reynolds JV, Mercer P, McDermott EW, Cross S, Stokes M, Murphy D, et al. Audit of complete axillary dissection in early breast cancer. Eur J Cancer 1994; 30A:148-149.
12. Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. Cancer 1998; 83(12 suppl American):2776-2781.
13. Velanovich V, Szymanski W. Quality of life of breast cancer patients with lymphedema. Am J Surg 1999; 177:184-187.
14. Hack TF, Cohen L, Katz J, Robson LS, Goss P. Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol 1999; 17:143-149.
15. Canavese G, Gipponi M, Catturich A, Di Somma C, Vecchio C, Rosato F, et al. Sentinel lymph node mapping opens a new perspective in the surgical management of early-stage breast cancer: a combined approach with vital blue dye lymphatic mapping and radioguided surgery. Semin Surg Oncol 1998; 15:272-277.
16. Maunsell E, Brisson J, Deschenes L. Arm problems and psychological distress after surgery for breast cancer. Can J Surg 1993; 36:315-320.
17. Cady B. Is axillary lymph node dissection necessary in routine management of breast cancer? No. Important Adv Oncol 1996; 251-265.
18. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society. American Cancer Society guidelines for the early detection of cancer, 2004. CA Cancer J Clin 2004; 54:41-52.
19. Cady B, Stone MD, Schuler JG, Thakur R, Wanner MA, Lavin PT. The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996; 131:301-308.
20. Miltenburg DM, Miller C, Karamlou TB, Brunicardi FC. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999; 84:138-142.
21. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer 1994; 73:664-667.
22. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220:339-401.
23. Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. J Am Med Assoc 1996; 276:1818-1822.
24. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer - a multicenter validation study. N Engl J Med 1998; 339:941-946.
25. Brady MS, Coit DG. Sentinel lymph node evaluation in melanoma. Arch Dermatol 1997; 133:1014-1020.
26. Stewart KC, Lyster DM. Interstitial lymphoscintigraphy for lymphatic mapping in surgical practice and research. J Invest Surg 1997; 10:249-262.
27. Cody HS 3rd, Borgen PI. State-of-the-art approaches to sentinel node biopsy for breast cancer: study design, patient selection, technique, and quality control at Memorial Sloan-Kettering Cancer Center. Surg Oncol 1999; 8:85-91.
28. Dauway EL, Giuliano R, Haddad F, Pendas S, Costello D, Cox CE, et al. Lymphatic mapping in breast cancer. Hematol Oncol Clin North Am 1999; 13:349-371.
29. Hill ADK, Mann GB, Borgen PI, Cody HS. Sentinel lymphatic mapping breast cancer. J Am Coll Surg 1999; 188:545-549.
30. Alazraki NP, Styblo T, Grant SF, Cohen C, Larsen T, Aarsvold JN. Sentinel node staging of early breast cancer using lymphoscintigraphy and the intraoperative gamma-detecting probe. Semin Nucl Med 2000; 30:56-64.
31. Paganelli G, De Cicco C, Chinol M. Sentinel node localization by lymphoscintigraphy: a reliable technique with widespread applications. Recent Results Cancer Res 2000; 157:121-129.
32. Krag DN, Harlow S. Current status of sentinel node surgery in breast cancer. Oncology 2003; 17:1663-1666.
33. Lu YS, Kuo SH, Huang CS. Recent advances in the management of primary breast cancers. J Formos Med Assoc 2004; 103:579-598.
34. Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000; 88:608-614.
35. Sener SF, Winchester DJ, Martz CH, Feldman JL, Cavanaugh JA, Winchester DP, et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma. Cancer 2001; 92:748-752.
36. Jani AB, Basu A, Heimann R, Hellman S. Sentinel lymph node versus axillary lymph node dissection for early-stage breast carcinoma: a comparison using a utility-adjusted number needed to treat analysis. Cancer 2003; 97:359-366.
37. Jeffrey SS, Jones SB, Smith K. Controversies in sentinel lymph node biopsy for breast cancer. Cancer Biother Radiopharm 2000; 15:223-233.
38. Chao C, McMasters K. The current status of sentinel lymph node biopsy for breast cancer. Adv Surg 2002; 36:167-192.
39. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399.
40. Alex JC, Krag DN. Gamma-probe guided localization of lymph nodes. Surg Oncol 1993; 2:137-143.
41. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2:335-340.
42. Veronesi U, Luini A, Galimberti V, Marchini S, Sacchini V, Rilke F. Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol 1990; 16:127-133.
43. Martin RC 2nd, Edwards MJ, Wong SL, Tuttle TM, Carlson DJ, Brown CM, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. Surgery 2000; 128:139-144.
44. Lagares-Garcia JA, Garguilo G, Kurek S, LeBlond G, Diaz F. Axillary lymph node dissection in breast cancer: an evolving question? Am Surg 2000; 66:66-72.
45. Cody HS 3rd. Sentinel lymph node mapping in breast cancer. Oncology 1999; 13:25-34.
46. Cody HS 3rd, Hill AD, Tran KN, Brennan MF, Borgen PI. Credentialing for breast lymphatic mapping: how many cases are enough? Ann Surg 1999; 229:723-726.
47. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997; 15:2345-2350.
48. Guenther JM, Krishnamoorthy M, Tan LR. Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am 1997; 3:336-340.
49. Eary JF, Mankoff DA, Dunnwald LK, Byrd DR, Anderson BO, Yeung RS, et al. Sentinel lymph node mapping for breast cancer: analysis in a diverse patient group. Radiology 1999; 213:526-529.
50. Flett MM, Going JJ, Stanton PD, Cooke TG. Sentinel node localization in patients with breast cancer. Br J Surg 1998; 85:991-993.
51. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349:1864-1867.
52. Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998; 186:275-283.
53. Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 1998; 227:645-651.
54. Burak WE Jr, Walker MJ, Yee LD, Kim JA, Saha S, Hinkle G, et al. Routine preoperative lymphoscintigraphy is not necessary prior to sentinel node biopsy for breast cancer. Am J Surg 1999; 177:445-449.
55. Motomura K, Inaji H, Komoike Y, Hasegawa Y, Kasugai T, Noguchi S, et al. Combination technique is superior to dye alone in identification of the sentinel node in breast cancer patients. J Surg Oncol 2001; 76:95-99.
56. Meijer S, Pijpers R, Borgstein PJ, Bleichrodt RP, van Diest PJ. The sentinel node procedure: standard intervention for surgical treatment of breast cancer. Ned Tijdschr Geneeskd 1998; 142:2235-2237.
57. McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000; 18:2560-2566.
58. Krag DN, Harlow S, Weaver D, Ashikaga T. Radiolabeled sentinel node biopsy: collaborative trial with the National Cancer Institute. World J Surg 2001; 25:823-828.
59. Celliers L, Mann GB. Alternative sites of injection for sentinel lymph node biopsy in breast cancer. Aust NZ J Surg 2003; 73:600-604.
60. Linehan DC, Hill AD, Akhurst T, Yeung H, Yeh SD, Tran KN, et al. Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann Surg Oncol 1999; 6:450-454.
61. Schwartz GF, Giuliano AE, Veronesi U, Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94:2542-2551.
62. Shimazu K, Tamaki Y, Taguchi T, Takamura Y, Noguchi S. Comparison between periareolar and peritumoral injection of radiotracer for sentinel lymph node biopsy in patients with breast cancer. Surgery 2002; 131:277-286.
63. Klimberg VS, Rubio IT, Henry R, Cowan C, Colvert M, Korourian S. Subareolar versus peritumoral injections for location of the sentinel lymph node. Ann Surg 1999; 229:860-864.
64. McMasters KM, Wong SL, Martin RC 2nd, Chao C, Tuttle TM, Noyes RD, et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg 2001; 233:676-687.
65. Borgstein PJ, Meijer S, Pijpers RJ, van Diest PJ. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg 2000; 232:81-89.
66. Kern KA. Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye. J Am Coll Surg 1999; 189:539-545.
67. Kern KA, Rosenberg RJ. Preoperative lymphoscintigraphy during lymphatic mapping for breast cancer: improved sentinel node imaging using subareolar injection of technetium 99m sulfur colloid. J Am Coll Surg 2000; 191:479-489.
68. Vargas HI, Tolmos J, Agbunag RV, Mishkin F, Vargas MP, Diggles L, et al. A validation trial of subdermal injection compared with intraparenchymal injection for sentinel lymph node biopsy in breast cancer. Am Surg 2002; 68:87-91.
69. Paganelli G, Galimberti V, Trifiro G, Travaini L, De Cicco C, Mazzarol G, et al. Internal mammary node lymphoscintigraphy and biopsy in breast cancer. Q J Nucl Med 2002; 45:138-144.
70. Tanis PJ, Deurloo EE, Valdes Olmos RA, Rutgers EJ, Nieweg OE, Besnard AP, et al. Single intralesional tracer dose for radio-guided excision of clinically occult breast cancer and sentinel node. Ann Surg Oncol 2001; 8:850-855.
71. Solorzano CC, Ross MI, Delpassand E, Mirza N, Akins JS, Kuerer HM, et al. Utility of breast sentinel lymph node biopsy using day-before-surgery injection of high-dose 99mTc-labeled sulfur colloid. Ann Surg Oncol 2001; 8:821-827.
72. Tafra L, Lannin DR, Swanson MS, Van Eyk JJ, Verbanac KM, Chua AN, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 2001; 233:51-59.
73. O’Hea BJ, Hill AD, El-Shirbiny AM, Yeh SD, Rosen PP, Coit DG, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998; 186:423-427.
74. Wong SL, Chao C, Edwards MJ, Tuttle TM, Noyes RD, Carlson DJ, et al. Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers. Am Surg 2001; 67:522-526.
75. Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (> or=5舁cm) invasive breast cancer. Ann Surg Oncol 2001; 8:688-692.
76. Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999; 91:368-373.
77. Goyal A, Horgan K, Kissin M, Yiangou C, Sibbering M, Lansdown M, et al., on behalf of the ALMANAC Trialists Group. Sentinel lymph node biopsy in male breast cancer patients. Eur J Surg Oncol 2004; 30:480-483.
78. Krontiras H, Bland KI. When is sentinel node biopsy for breast cancer contraindicated? Surg Oncol 2003; 12:207-210.
79. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002; 9:235-242.
80. National Comprehensive Cancer Network Practice Guidelines in Oncology. Invasive Breast Cancer Vol. 1. Jenkintown, PA: National Comprehensive Cancer Network; 2002.
81. Hill AD, Tran KN, Akhurst T, Yeung H, Yeh SD, Rosen PP, et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg 1999; 229:528-535.
82. American Society of Breast Surgeons. Consensus statement on guidelines for performance of sentinel lymphadenectomy for breast cancer. Columbia, MD: American Society of Breast Surgeons; 2002. Available at: http://www.breastsurgeons.org/officialstmts/sentinel.shtml
83. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16:2253-2260.
84. Rosen PP, Lesser ML, Kinne DW, Beattie EJ. Discontinuous or “skip” metastases in breast carcinoma. Analysis of 1228 axillary dissections. Ann Surg 1983; 197:276-283.
85. Rubio IT, Korourian S, Cowan C, Krag DN, Colvert M, Klimberg VS. Sentinel lymph node biopsy for staging breast cancer. Am J Surg 1998; 176:532-537.
86. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000; 18:2553-2559.
87. Luini A, Gatti G, Frasson A, Naninato P, Magalotti C, Arnone P, et al. Sentinel lymph node biopsy performed with local anesthesia in patients with early-stage breast carcinoma. Arch Surg 2002; 137:1157-1160.
88. Liang WC, Sickle-Santanello BJ, Nims TA. Is a completion axillary dissection indicated for micrometastases in the sentinel lymph node? Am J Surg 2001; 182:365-368.
89. Chung MA, Steinhoff MM, Cady B. Clinical axillary recurrence in breast cancer patients after a negative sentinel node biopsy. Am J Surg 2002; 184:310-314.
90. Kelley MC, Hansen N, McMasters KM. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Am J Surg 2004; 188:49-61.
91. Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg 2004; 240:462-468.
92. Chagpar A, Martin RC 3rd, Chao C, Wong SL, Edwards MJ, Tuttle T, et al. Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy. Arch Surg 2004; 139:614-618.
93. Mariotti S, Buonomo O, Guadagni F, Spila A, Schiaroli S, Cipriani C, et al. Minimal sentinel node procedure for staging early breast cancer. Tumori 2002; 88:S45-S47.
94. Borgstein PJ, Meijer S, Pijpers R. Intradermal blue dye to identify sentinel lymph-node in breast cancer. Lancet 1997; 349:1668-1669.
95. Nieweg OE, Kapteijn BA, Peterse JL, Rutgers EJ, van Dongen JA, Kroon BB. Identification of the sentinel node in patients with breast carcinoma. Ned Tijdschr Geneeskd 1996; 140:2235-2239.
96. Kumar R, Potenta S, Alavi A. Sentinel lymph node biopsy in multifocal and multicentric breast cancer. J Am Coll Surg 2004; 198:674-676.
97. Mertz L, Mathelin C, Marin C, Gairard B, Chenard MP, Brettes JP, et al. Subareolar injection of 99m-Tc sulfur colloid for sentinel node identification in multifocal invasive breast cancer. Bull Cancer 1999; 86:939-945.
98. Delaloye JF, Antonescu C, Besseghir N, Genton CY, Bischof-Delaloye A, De Grandi P. Sentinel lymph node biopsy in breast cancer: the Lausanne experience. Rev Med Suisse Romande 2000; 120:491-494.
99. Offodile R, Hoh C, Barsky SH, Nelson SD, Elashoff R, Eilber FR, et al. Minimally invasive breast carcinoma staging using lymphatic mapping with radiolabeled dextran. Cancer 1998; 82:1704-1708.
100. Gulec SA, Moffat FL, Carroll RG, Serafini AN, Sfakianakis GN, Allen L, et al. Sentinel lymph node localization in early breast cancer. J Nucl Med 1998; 39:1388-1393.
101. Feggi LM, Querzoli P, Prandini N, Corcione S, Bergossi L, Basaglia E, et al. Sentinel node study in early breast cancer. Tumori 2000; 86:314-316.
102. Meijer S, Collet GJ, Pijpers HJ, van Hattum L, Hoekstra OS. Less axillary dissection necessary due to sentinel node biopsy in patients with breast carcinoma. Ned Tijdschr Geneeskd 1996; 140:2239-2243.
103. Knox SM, Ley CA. Comparison of intraparenchymal and intradermal injection for identification of the sentinel node in patients with breast cancer. BUMC Proc 2002; 15:366-368.
104. Barnwell JM, Arredondo MA, Kollmorgen D, Gibbs JF, Lamonica D, Carson W, et al. Sentinel node biopsy in breast cancer. Ann Surg Oncol 1998; 5:126-130.
105. Kapteijn BA, Nieweg OE, Petersen JL, Rutgers EJ, Hart AA, van Dongen JA, et al. Identification and biopsy of the sentinel lymph node in breast cancer. Eur J Surg Oncol 1998; 24:427-430.
106. Pijpers R, Meijer S, Hoekstra OS, Collet GJ, Comans EF, Boom RP, et al. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer. J Nucl Med 1997; 38:366-368.
107. Alex JC, Krag DN. The gamma-probe-guided resection of radiolabeled primary lymph nodes. Surg Oncol Clin N Am 1996; 5:33-41.
108. Dale PS, Williams JT 4th. Axillary staging utilizing selective sentinel lymphadenectomy for patients with invasive breast carcinoma. Am Surg 1998; 64:28-31.
109. Lauridsen MC, Garne JP, Sorensen FB, Melsen F, Lernevall A, Christiansen P. Sentinel lymph node biopsy in breast cancer - experience with the combined use of dye and radioactive tracer at Aarhus University Hospital. Acta Oncol 2004; 43:20-26.
110. Jaderborg JM, Harrison PB, Kiser JL, Maynard SL. The feasibility and accuracy of the sentinel lymph node biopsy for breast carcinoma. Am Surg 1999; 65:699-703.
111. Bass SS, Dauway E, Mahatme A, Ku NN, Berman C, Reintgen D, et al. Lymphatic mapping with sentinel lymph node biopsy in patients with breast cancers <1 centimeter (T1A-T1B). Am Surg 1999; 65:857-861.
112. De Cicco C, Cremonesi M, Luini A, Bartolomei M, Grana C, Prisco G, et al. Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med 1998; 39:2080-2084.
113. Bedrosian I, Reynolds C, Mick R, Callans LS, Grant CS, Donohue JH, et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 2000; 88:2540-2545.
114. Giuliano AE, Barth AM, Spivack B, Beitsch PD, Evans SW. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast. J Am Coll Surg 1996; 183:185-189.
115. van der Ent FW, Kengen RA, van der Pol HA, Hoofwijk AG. Sentinel node biopsy in 70 unselected patients with breast cancer: increased feasibility by using 10舁mCi radiocolloid in combination with a blue dye tracer. Eur J Surg Oncol 1999; 25:24-29.
116. Nwariaku FE, Euhus DM, Beitsch PD, Clifford E, Erdman W, Mathews D, et al. Sentinel lymph node biopsy, an alternative to elective axillary dissection for breast cancer. Am J Surg 1998; 176:529-531.
117. Fleming FJ, Hill AD, Kavanagh D, Quinn C, O’Doherty A, Collins CD, et al. Intradermal radioisotope injection optimises sentinel lymph node identification in breast cancer. Eur J Surg Oncol 2003; 29:835-838.
118. Roumen RMH, Valkenburg JGM, Geuskens LM. Lymphoscintigraphy and feasibility of sentinel node biopsy in 83 patients with primary breast cancer. Eur J Surg Oncol 1997; 23:495-502.
119. Martin RC, Derossis AM, Fey J, Yeung H, Yeh SD, Akhurst T, et al. Intradermal isotope injection is superior to intramammary in sentinel node biopsy for breast cancer. Surgery 2001; 130:432-438.
120. d‘Eridita G, Serio G, Mele M, Giardina C, Martellotta M, Ferrarese F. Effect of the use of vital dye, lymphoscintigraphy, or a combination for axillary lymphatic mapping and sentinel node biopsy in breast cancer. World J Surg 2002; 26:588-590.
121. Bobin JY, Zinzindohoue C, Isaac S, Saadat M, Roy P. Tagging sentinel lymph nodes: a study of 100 patients with breast cancer. Eur J Cancer 1999; 35:569-573.
122. Motomura K, Komoike Y, Hasegawa Y, Kasugai T, Inaji H, Noguchi S, et al. Intradermal radioisotope injection is superior to subdermal injection for the identification of the sentinel node in breast cancer patients. J Surg Oncol 2003; 82:91-96.
123. Doting MH, Jansen L, Nieweg OE, Piers DA, Tiebosch AT, Koops HS, et al. Lymphatic mapping with intralesional tracer administration in breast carcinoma patients. Cancer 2000; 88:2546-2552.
124. Koller M, Barsuk D, Zippel D, Engelberg S, Ben-Ari G, Papa MZ. Sentinel lymph node involvement - a predictor for axillary node status with breast cancer - has the time come? Eur J Surg Oncol 1998; 24:166-168.
125. Schneebaum S, Stadler J, Cohen M, Yaniv D, Baron J, Skornick Y. Gamma probe-guided sentinel node biopsy - optimal timing for injection. Eur J Surg Oncol 1998; 24:515-519.
126. Snider H, Dowlatshahi K, Fan M, Bridger WM, Rayudu G, Oleske D. Sentinel node biopsy in the staging of breast cancer. Am J Surg 1998; 176:305-310.
127. Birdwell RL, Smith KL, Betts BJ, Ikeda DM, Strauss HW, Jeffrey SS. Breast cancer: variables affecting sentinel lymph node visualization at preoperative lymphoscintigraphy. Radiology 2001; 220:47-53.
128. Winchester DJ, Sener SF, Winchester DP, Perlman RM, Goldschmidt RA, Motykie G, et al. Sentinel lymphadenectomy for breast cancer: experience with 180 consecutive patients: efficacy of filtered technetium 99m sulphur colloid with overnight migration time. J Am Coll Surg 1999; 188:597-603.
129. Boolbol SK, Fey JV, Borgen PI, Heerdt AS, Montgomery LL, Paglia M, et al. Intradermal isotope injection: a highly accurate method of lymphatic mapping in breast carcinoma. Ann Surg Oncol 2001; 8:20-24.
130. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349:546-553.
131. Ilum L, Bak M, Olsen KE, Kryh D, Berg V, Axelsson CK. Sentinel node localization in breast cancer patients using intradermal dye injection. Acta Oncol 2000; 39:423-428.
132. Crossin JA, Johnson AC, Stewart PB, Turner WW Jr. Gamma-probe-guided resection of the sentinel lymph node in breast cancer. Am Surg 1998; 64:666-668.
133. Morrow M, Rademaker AW, Bethke KP, Talamonti MS, Dawes LG, Clauson J, et al. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery 1999; 126:714-720.
134. Miner TJ, Shriver CD, Jaques DP, Maniscalco-Theberge ME, Krag DN. Ultrasonographically guided injection improves localization of the radiolabeled sentinel lymph node in breast cancer. Ann Surg Oncol 1998; 5:315-321.
135. Povoski SP, Dauway EL, Ducatman BS. Sentinel lymph node mapping and biopsy for breast cancer at a rural-based university medical center: initial experience with intraparenchymal and intradermal injection routes. Breast Cancer 2002; 9:134-144.
136. Sato K, Uematsu M, Saito T, Ishikawa H, Yamasaki T, Tamaki K, et al. Indications and technique of sentinel lymph node biopsy in breast cancer using 99m-technetium labeled tin colloids. Breast Cancer 2000; 7:95-98.
137. McCarter MD, Yeung H, Yeh S, Fey J, Borgen PI, Cody HS 3rd. Localization of the sentinel node in breast cancer: identical results with same-day and day-before isotope injection. Ann Surg Oncol 2001; 8:682-686.
138. Cody HS 3rd, Fey J, Akhurst T, Fazzari M, Mazumdar M, Yeung H, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol 2001; 8:13-19.
139. Beitsch PD, Clifford E, Whitworth P, Abarca A. Improved lymphatic mapping technique for breast cancer. Breast J 2001; 7:219-223.
140. Paganelli G, De Cicco C, Cremonesi M, Prisco G, Calza P, Luini A, et al. Optimized sentinel node scintigraphy in breast cancer. Q J Nucl Med 1998; 42:49-53.
141. Derossis AM, Fey J, Yeung H, Yeh SD, Heerdt AS, Petrek J, et al. A trend analysis of the relative value of blue dye and isotope localization in 2000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg 2001; 193:473-478.
142. Shen P, Glass EC, DiFronzo LA, Giuliano AE. Dermal versus intraparenchymal lymphoscintigraphy of the breast. Ann Surg Oncol 2001; 8:241-248.
143. Czerniecki BJ, Scheff AM, Callans LS, Spitz FR, Bedrosian I, Conant EF, et al. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 1999; 85:1098-1103.
144. Vazquez Forner C, Gimenez Climent J, Fliquete Peris MV, Fuster Diana C, Mas Arcas C, Vazquez Albaladejo C. Locating the sentinel node in breast cancer by gamma probe and staining agent. Preliminary study. Rev Esp Med Nucl 2000; 19:207-210.
145. Tsunoda N, Iwata H, Sarumaru S, Mizutani M, Iwase T, Miura S. Combination of subareolar blue dye and peritumoral RI for sentinel lymph node biopsy. Breast Cancer 2002; 9:323-328.
146. Linehan DC, Hill AD, Tran KN, Yeung H, Yeh SD, Borgen PI, et al. Sentinel lymph node biopsy in breast cancer: unfiltered radioisotope is superior to filtered. J Am Coll Surg 1999; 188:377-381.
147. Fortunato L, Benzoni C, Amini M, Alessi G, Manni C, Andrich R, et al. Sentinel lymph node for breast cancer: remove less to know more. Minerva Chir 2001; 56:439-449.
148. Uren RF, Howman-Giles RB, Thompson JF, Malouf D, Ramsey-Stewart G, Niesche FW, et al. Mammary lymphoscintigraphy in breast cancer. J Nucl Med 1995; 36:1775-1780.
149. Imoto S, Murakami K, Ikeda H, Fukukita H, Moriyama N. Mammary lymphoscintigraphy with various radiopharmaceuticals in breast cancer. Ann Nucl Med 1999; 13:325-329.